Form 13-F position report

PHOENIX BIOTECH ACQUISITION

Reported by MANGROVE PARTNERS

CEROW CUSIP 71902K113 Manager CIK 0001535392

Reported 163,538 shares, unchanged from the prior quarter.

Reported value 2.1%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 0.12% This manager · Q2 2023
Shares 163,538 Quarter-end amount reported
Reported value $1,782,564 Fair value at quarter end
Consecutive quarters held 7 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 1621000
2022-03-31 1636000
2022-06-30 1639000
2022-09-30 1650000
2022-12-31 1679584
2023-03-31 1746586
2023-06-30 1782564
2023-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

8 quarters
Quarterly reported position history for PHOENIX BIOTECH ACQUISITION held by MANGROVE PARTNERS.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2023 Reduced 0 -163,538 (-100.0%) 0 $0 2023-11-14
Q2 2023 Unchanged 163,538 0 (0.0%) 0.12% $1,782,564 2023-08-14
Q1 2023 Unchanged 163,538 0 (0.0%) 0.11% $1,746,586 2023-05-15
Q4 2022 Unchanged 163,538 0 (0.0%) 0.09% $1,679,584 2023-02-14
Q3 2022 Unchanged 163,538 0 (0.0%) 0.1% $1,650,000 2022-11-14
Q2 2022 Unchanged 163,538 0 (0.0%) 0.08% $1,639,000 2022-08-15
Q1 2022 Unchanged 163,538 0 (0.0%) 0.09% $1,636,000 2022-05-16
Q4 2021 New 163,538 +163,538 (0.0%) 0.1% $1,621,000 2022-02-14

Who else reported the position

49 managers reported PHOENIX BIOTECH ACQUISITION for Q2 2023.

Managers reporting PHOENIX BIOTECH ACQUISITION in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
MANGROVE PARTNERS This report Unchanged 163,538 0 0.12% $1,782,564 7 qtrs
Periscope Capital Inc Unchanged 957,098 0 < 0.01% $61,858 6 qtrs
Segantii Capital Management Ltd Unchanged 5,000 0 < 0.01% $54,500 7 qtrs
HIGHBRIDGE CAPITAL MANAGEMENT LLC Added 714,827 +136,983 < 0.01% $43,604 7 qtrs
MMCAP International Inc SPC Unchanged 375,000 0 < 0.01% $22,913 7 qtrs
CANTOR FITZGERALD L P Unchanged 363,548 0 < 0.01% $22,213 7 qtrs
Saba Capital Management L P Unchanged 295,913 0 < 0.01% $19,368 7 qtrs
Polar Asset Management Partners Inc Unchanged 300,000 0 < 0.01% $18,330 7 qtrs
Linden Advisors LP Unchanged 249,999 0 < 0.01% $16,375 6 qtrs
AQR Arbitrage LLC Reduced 246,696 -286 < 0.01% $15,073 7 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 14, 2023
Filing type
13F-HR
Position type
*W EXP 09/01/202

Voting authority reported

Sole
163,538
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.